文献速递心脑血管急症重症综合管理与镇静镇痛

评估自发性脑出血中血压指标的临床相关性:ATACH-2 事后分析

Assessing the Clinical Relevance of Blood Pressure Measures in Spontaneous Intracerebral Hemorrhage: A Post Hoc Analysis of ATACH-2.
PubMed 文献 · Neurocrit Care · 2025-09-04
一句话结论ATACH-2 事后分析提示,收缩压变异性虽有统计学差异,但未超过 10 mmHg 最小可检测差异阈值,临床相关性有限。

该研究为 ATACH-2 随机临床试验的事后分析,纳入自发性脑出血患者,比较预后良好(改良 Rankin 量表 0-3 分)与预后不良(改良 Rankin 量表 4-6 分)两组在达标收缩压、收缩压变异性和收缩压下降幅度三项指标上的差异,以 10 mmHg 最小可检测差异作为临床意义阈值。结果显示,仅前 24 小时收缩压变异性在两组间有统计学差异,但平均差异(95% CI)未超过 10 mmHg 阈值;达标收缩压和收缩压下降幅度组间无显著差异。倾向性评分匹配分析中,任何血压指标与预后均无统计学差异。作者认为,事后分析结果用于临床决策需谨慎。

要点

  • 预后良好(mRS 0-3)与不良(mRS 4-6)组间前 24 小时收缩压变异性虽有统计学差异,但平均差异(95% CI)未超过 10 mmHg 最小可检测差异阈值。
  • 达标收缩压与收缩压下降幅度在预后良好组与不良组间无显著差异。
  • 倾向性评分匹配分析显示,任何血压测量指标与预后之间均无统计学差异。
  • 作者认为,收缩压变异性的统计学差异处于测量噪声范围内,未达临床相关性阈值。
  • 作者强调,事后分析结果用于临床决策需谨慎。

适用人群与场景

  • ATACH-2 随机临床试验中的自发性脑出血患者,比较预后良好(改良 Rankin 量表 0-3 分)与预后不良(改良 Rankin 量表 4-6 分)两组。

诊断标准与关键阈值

  • 以 10 mmHg 作为最小可检测差异阈值,差异超过该阈值才认为具有临床意义。
  • 预后良好定义为改良 Rankin 量表评分 0-3 分;预后不良定义为改良 Rankin 量表评分 4-6 分。

研究设计与关键结果

  • 研究类型为 ATACH-2 随机临床试验的事后分析,评估达标收缩压、收缩压变异性和收缩压下降幅度在预后良好与不良组间的差异。
  • 前 24 小时收缩压变异性在两组间有统计学差异,但平均差异(95% CI)未超过 10 mmHg 最小可检测差异阈值。
  • 达标收缩压和收缩压下降幅度在预后良好组与不良组间无显著差异。
  • 倾向性评分匹配分析中,任何血压测量指标与预后之间均无统计学差异。

证据类型、等级与局限

  • 证据类型为随机临床试验的事后分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,尽管前 24 小时收缩压变异性在预后良好与不良组间有统计学差异,但该差异处于测量噪声范围内,未达临床相关性阈值。
  • 作者认为,倾向性评分匹配分析提示血压汇总指标与预后的关联对分析方法不稳健。
  • 作者强调,解读事后分析结果用于临床决策需谨慎。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Recent American Heart Association guidelines have relied on post hoc subgroup analyses to identify summary blood pressure measures for targets in early management of acute intracerebral hemorrhage. To our knowledge, measurement error has not been considered when determining the impact of these summary measures. Our objective was to determine whether statistically significant differences in three systolic blood pressure (SBP) measures (achieved SBP, SBP variability, and magnitude of SBP reduction) in patients with intracerebral hemorrhage from the antihypertensive treatment of acute cerebral hemorrhage II (ATACH-2) randomized clinical trial are clinically meaningful by comparing them to a minimally detectable difference (MDD) of 10 mm Hg.

METHODS: We performed a post hoc analysis of individual patient data from the ATACH-2 randomized clinical trial, evaluating the differences in achieved SBP, SBP variability, and magnitude of SBP reduction between patients with favorable (modified Rankin scale score 0-3) and unfavorable (modified Rankin scale score 4-6) outcomes. We used the empirical cumulative distribution functions and Kolmogorov-Smirnov tests to compare distributions, and we considered differences clinically meaningful if they exceeded the MDD of 10 mm Hg. We also performed a propensity score matched analysis to understand the nature of the association between these measures and outcomes.

RESULTS: Although SBP variability in the first 24 h differed statistically between outcome groups, the mean difference (95% confidence interval) did not exceed the MDD threshold. Achieved SBP and magnitude of SBP reduction showed no significant differences between groups. In the propensity score matched analysis, there were no statistical differences between any blood pressure measurements and outcomes.

CONCLUSIONS: Our findings suggest that although there are statistically significant differences in SBP variability between patients with good and poor outcomes in ATACH-2, these differences do not meet the threshold for clinical relevance because they were within the range of measurement noise. The propensity score matched analysis suggested that the association between summary blood pressure measurements and outcomes is not robust to analytical method. These findings emphasize the need for caution in interpreting post hoc findings for clinical decision-making.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Garg R, Torrealba-Acosta G, Mandava P, et al. Assessing the Clinical Relevance of Blood Pressure Measures in Spontaneous Intracerebral Hemorrhage: A Post Hoc Analysis of ATACH-2. Neurocrit Care. 2025. PMID: 40908415. doi:10.1007/s12028-025-02350-w

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。